

Press Release

Matthias Link
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2872
F +49 6172 608-2294
matthias.link@fresenius.com
www.fresenius.com

May 13, 2016

Fresenius SE & Co. KGaA Annual General Meeting: 2016 guidance confirmed, 23rd straight dividend increase approved

Fresenius expects new records for sales and earnings in the current business year. At the Annual General Meeting in Frankfurt today, Ulf Mark Schneider, CEO of Fresenius, confirmed the 2016 targets. The company is forecasting sales growth of 6 to 8 percent and an increase of 8 to 12 percent in net income, both in constant currency.

In his speech, Schneider also confirmed the company's mid-term financial goals: "For fiscal 2019 we are targeting sales of €36 to €40 billion, and net income between €2 and €2.25 billion. This means a doubling of our net income within a period of just five years, and a fourfold increase in one decade."

Schneider said that by combining a disciplined growth focus with operational and structural stability, the company has built a solid basis for excellent long-term performance. "2015 marked our 12th consecutive record year and delivered our 23rd straight dividend increase," the Fresenius CEO added. "These results demonstrate that we are continuing to generate strong, stable growth over time."

Shareholders approved with a majority of 90.68% the 23rd consecutive dividend increase proposed by the general partner and the Supervisory Board. The dividend was raised by 25% to €0.55 per share.

With clear majorities, the shareholders elected all candidates for a new Supervisory Board. Prof. Dr. med. Iris Löw-Friedrich, Chief Medical Officer and Executive Vice President of UCB S.A., and Hauke Stars, a Member of the Management Board of Deutsche Börse AG, were elected to the 12-member body for the first time, as shareholder representatives.

Shareholder majorities of 99.64% and 99.52%, respectively, approved the actions of the Management and Supervisory Boards in 2015.

At the Annual General Meeting, 72.73% of the subscribed capital was represented.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2015, Group sales were €27.6 billion. On March 31, 2016, the Fresenius Group had 223,704 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

Follow us on Facebook and Twitter: www.facebook.com/fresenius_group and <http://www.twitter.com/fresenius>.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz,
Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick